Richard D Carvajal

List of Publications by Year
in descending order

159	10,116	76196	39575
papers	citations	40	94
		h-index	g-index

163	163	163	13242
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 2015, 33, 3193-3198.	0.8	892
2	KIT as a Therapeutic Target in Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2011, 305, 2327.	3.8	755
3	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Science Translational Medicine, 2014, 6, 260ra149.	5.8	589
4	Uveal melanoma. Nature Reviews Disease Primers, 2020, 6, 24.	18.1	392
5	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Nonâ€“Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology, 2019, 5, 1411.	3.4	388
6	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	13.9	376
7	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. JAMA - Journal of the American Medical Association, 2014, 311, 2397.	3.8	359
8	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. Cancer, 2016, 122, 3344-3353.	2.0	288
9	Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 2017, 101, 38-44.	2.1	287
10	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery, 2018, 8, 184-195.	7.7	283
11	Aurora Kinases: New Targets for Cancer Therapy. Clinical Cancer Research, 2006, 12, 6869-6875.	3.2	258
12	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	1.1	252
13	Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clinical Ophthalmology, 2017, Volume 11, 279-289.	0.9	240
14	Treatment of uveal melanoma: where are we now?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875717.	1.4	224
15	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	0.8	207
16	Clinical activity of ipilimumab for metastatic uveal melanoma. Cancer, 2013, 119, 3687-3695.	2.0	171
17	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	1.9	154
18	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. Cancer Immunology Research, 2015, 3, 288-295.	1.6	145

#	Article	IF	Citations
19	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	1.9	140
20	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clinical Cancer Research, 2013, 19, 2257-2264.	3.2	136
21	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research, 2015, 21, 2289-2296.	3.2	128
22	Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors. Hematology/Oncology Clinics of North America, 2005, 19, 501-525.	0.9	124
23	Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 345-356.	2.3	117
24	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	3.2	106
25	Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma. Clinical Cancer Research, 2011, 17, 2087-2100.	3.2	103
26	GNAQ and GNA11 mutations in uveal melanoma. Melanoma Research, 2014, 24, 525-534.	0.6	99
27	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
28	Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance. Clinical Cancer Research, 2012, 18, 3552-3561.	3.2	91
29	Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 2019, 11, 971.	1.7	87
30	Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.		82
31	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) Â± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
32	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Current Oncology Reports, 2017, 19, 45.	1.8	70
33	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		66
34	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head and Neck, 2016, 38, 1310-1317.	0.9	65
35	KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. American Journal of Clinical Dermatology, 2019, 20, 315-323.	3.3	64
36	Hybrid Captureâ€"Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	3.2	59

#	Article	IF	Citations
37	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptorâ€“related protein agonist AMG 228 in patients with advanced solid tumors. , 2018, 6, 93.		59
38	Phase I/II study of LAG525 Â± spartalizumab (PDR001) in patients (pts) with advanced malignancies.. Journal of Clinical Oncology, 2018, 36, 3012-3012.	0.8	58
39	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	1.9	57
40	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunology, Immunotherapy, 2017, 66, 1249-1264.	2.0	56
41	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	1.0	51
42	A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1281-1288.	3.2	50
43	Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Molecular Medicine, 2019, 11, .	3.3	49
44	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 460-472.	3.2	48
45	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642.	1.7	47
46	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
47	Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). BMC Cancer, 2015, 15, 467.	1.1	45
48	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clinical Cancer Research, 2020, 26, 1025-1033.	3.2	45
49	Arginine depletion as a therapeutic approach for patients with COVID-19. International Journal of Infectious Diseases, 2021, 102, 566-570.	1.5	45
50	CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.. Journal of Clinical Oncology, 2019, 37, 549-549.	0.8	44
51	A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.. Journal of Clinical Oncology, 2016, 34, 9511-9511.	0.8	42
52	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Molecular Cancer Therapeutics, 2020, 19, 1031-1039.	1.9	41
53	Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.. Journal of Clinical Oncology, 2018, 36, 9521-9521.	0.8	41
54	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecologic Oncology Reports, 2016, 16, 42-46.	0.3	40

#	Article	IF	Citations
55	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Research, 2017, 27, 57-64.	0.6	39
56	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist, 2015, 20, 648-652.	1.9	38
57	The promise and challenges of rare cancer research. Lancet Oncology, The, 2016, 17, 136-138.	5.1	38
58	Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2014, 32, 9030-9030.	0.8	38
59	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology, 2009, 9, 404-409.	0.5	37
60	Conjunctival Melanoma: Current Treatments and Future Options. American Journal of Clinical Dermatology, 2020, 21, 371-381.	3.3	33
61	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 6709-6720.	3.2	32
62	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
63	A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Research, 2016, 26, 272-277.	0.6	31
64	Inhibition of NF-Î²Bâ€“Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma. Cancer Research, 2019, 79, 2415-2425.	0.4	31
65	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. Journal of Clinical Oncology, 2018, 36, 11514-11514.	0.8	30
66	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 2022, 40, 1939-1948.	0.8	29
67	MicroRNAâ€based risk scoring system to identify earlyâ€stage oral squamous cell carcinoma patients at highâ€risk for cancerâ€specific mortality. Head and Neck, 2020, 42, 1699-1712.	0.9	27
68	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).. Journal of Clinical Oncology, 2016, 34, 4568-4568.	0.8	26
69	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	1.9	25
70	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).. Journal of Clinical Oncology, 2013, 31, CRA9003-CRA9003.	0.8	25
71	Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.. Journal of Clinical Oncology, 2018, 36, 2550-2550.	0.8	25
72	Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. Future Oncology, 2016, 12, 1331-1344.	1.1	24

#	Article	IF	Citations
73	Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.. Journal of Clinical Oncology, 2021, 39, 2549-2549.	0.8	21
74	Abstract CT068: A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma. Cancer Research, 2019, 79, CT068-CT068.	0.4	21
75	Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor. Molecular Cancer Research, 2022, 20, 661-669.	1.5	21
76	Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, 295-296.	0.6	20
77	A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.. Journal of Clinical Oncology, 2016, 34, 2581-2581.	0.8	20
78	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational New Drugs, 2018, 36, 103-113.	1.2	19
79	Advances in Prevention and Surveillance of Cutaneous Malignancies. American Journal of Medicine, 2020, 133, 417-423.	0.6	19
80	Programmed death 1 immune checkpoint inhibitors. Clinical Advances in Hematology and Oncology, 2015, 13, 858-68.	0.3	19
81	Treatment of Uveal Melanoma. Cancer Treatment and Research, 2016, 167, 281-293.	0.2	18
82	Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. , 2020, 8, e000908.		18
83	Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma. Cancer Research, 2020, 80, 1078-1087.	0.4	18
84	Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.. Journal of Clinical Oncology, 2017, 35, 9531-9531.	0.8	18
85	A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3KÎ± Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers, 2021, 13, 5504.	1.7	18
86	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Experimental Dermatology, 2016, 25, 553-554.	1.4	17
87	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4119-4126.	3.2	17
88	Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology, 2018, 36, 603-603.	0.8	17
89	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Frontiers in Oncology, 2021, 11, 734354.	1.3	17
90	Dual checkpoint inhibitor-associated eosinophilic enteritis. , 2019, 7, 310.		16

#	Article	IF	Citations
91	Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology. JCO Precision Oncology, 2020, 4, 1038-1048.	1.5	16
92	A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2575-2575.	0.8	16
93	Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97.	1.8	15
94	A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).. Journal of Clinical Oncology, 2016, 34, 3024-3024.	0.8	15
95	Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer, 2017, 25, 2155-2167.	1.0	14
96	Melanoma driver mutations and immune therapy. OncoImmunology, 2016, 5, e1051299.	2.1	13
97	Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma.. Journal of Clinical Oncology, 2014, 32, 9074-9074.	0.8	13
98	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1011-1011.	0.8	13
99	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget, 2015, 6, 19316-19327.	0.8	13
100	Treatments for Noncutaneous Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 507-521.	0.9	12
101	Landscape of genetic alterations in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2014, 32, 9043-9043.	0.8	11
102	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 439-445.	1.2	10
103	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. European Radiology, 2021, 31, 1853-1862.	2.3	10
104	Cellular therapy for the treatment of solid tumors. Transfusion and Apheresis Science, 2021, 60, 103056.	0.5	10
105	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. Cancer Research, 2021, 81, CT002-CT002.	0.4	10
106	New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. Cancer Gene Therapy, 2022, 29, 1819-1826.	2.2	10
107	Novel Approaches to the Systemic Management of Uveal Melanoma. Current Oncology Reports, 2020, 22, 104.	1.8	9
108	Dual Immunological Checkpoint Blockade for Uveal Melanoma. Journal of Clinical Oncology, 2021, 39, 554-556.	0.8	9

#	Article	IF	Citations
109	Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI).. Journal of Clinical Oncology, 2021, 39, 9535-9535.	0.8	9
110	Multiregional genetic evolution of metastatic uveal melanoma. Npj Genomic Medicine, 2021, 6, 70.	1.7	9
111	Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigatorâ€™s choice (IC) in first-line metastatic uveal melanoma.. Journal of Clinical Oncology, 2021, 39, 9527-9527.	0.8	8
112	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opinion on Biological Therapy, 2022, 22, 997-1004.	1.4	7
113	Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.. Journal of Clinical Oncology, 2021, 39, 9526-9526.	0.8	6
114	A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 2523-2523.	0.8	6
115	The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma. Clinical Cancer Research, 2018, 24, 3477-3479.	3.2	5
116	Perspectives in melanoma: meeting report from the â€œMelanoma Bridgeâ€•(December 5thâ€“7th, 2019,) Tj ETQq0 0 0 rgBT /Overlock	1.8	5
117	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. Journal of Clinical Oncology, 2016, 34, 9507-9507.	0.8	5
118	A phase 1 trial of the bifunctional EGFR/TGFÎ² fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2513-2513.	0.8	5
119	Adopting a new stance on immunotherapy for uveal melanoma. Lancet Oncology, The, 2017, 18, 702-704.	5.1	4
120	Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan. Ocular Oncology and Pathology, 2019, 5, 186-189.	0.5	4
121	First-in-human phase I study of the bifunctional EGFR/TGFÎ² fusion protein BCA101 in patients with EGFR-driven advanced solid cancers.. Journal of Clinical Oncology, 2021, 39, 3074-3074.	0.8	4
122	Selecting Patients for KIT Inhibition in Melanoma. Methods in Molecular Biology, 2014, 1102, 137-162.	0.4	4
123	377â€…AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcÎ³R co-targeting to promote antitumor immunologic effects. , 2020, , .		4
124	Clinical utility and reimbursement for expanded genomic panel testing in adult oncology.. Journal of Clinical Oncology, 2019, 37, 6593-6593.	0.8	4
125	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. Journal of Clinical Oncology, 2019, 37, 9592-9592.	0.8	4
126	Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission. , 2021, 9, e001219.		4

#	Article	IF	Citations
127	Use of antibody arrays to probe exosome and extracellular vesicle mediated functional changes in cells. Methods in Enzymology, 2020, 645, 43-53.	0.4	4
128	Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma. International Journal of Surgery Case Reports, 2020, 77, 591-594.	0.2	3
129	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Management, 2020, 7, MMT41.	0.1	3
130	Extracutaneous Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 85-98.	0.9	3
131	Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors. Clinical Transplantation, 2021, 35, e14264.	0.8	3
132	Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.. Journal of Clinical Oncology, 2021, 39, 3018-3018.	0.8	3
133	Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).. Journal of Clinical Oncology, 2021, 39, 9531-9531.	0.8	3
134	Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2634-2634.	0.8	3
135	Abstract CT038: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival. , 2021, , .		3
136	Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.. Journal of Clinical Oncology, 2018, 36, 9570-9570.	0.8	3
137	Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.. Journal of Clinical Oncology, 2019, 37, TPS9604-TPS9604.	0.8	3
138	JAK-ing up the Response to KITÂInhibition. Journal of Investigative Dermatology, 2018, 138, 6-8.	0.3	2
139	Mucosal melanoma: current strategies and future directions. Expert Opinion on Orphan Drugs, 2019, 7, 427-434.	0.5	2
140	401â€...Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , .		2
141	538â€...Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2
142	Update on the treatment of uveal melanoma. Clinical Advances in Hematology and Oncology, 2016, 14, 768-770.	0.3	2
143	Selumetinib for the treatment of melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 223-231.	0.5	1
144	Case of Merkel cell carcinoma in a patient with pre-existing ILD. , 2020, 8, e001672.		1

#	Article	IF	Citations
145	MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma. Journal of Oncology, 2021, 2021, 1-11.	0.6	1
146	Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).. Journal of Clinical Oncology, 2021, 39, e21513-e21513.	0.8	1
147	Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e21600-e21600.	0.8	1
148	819â€…Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp. , 2021, 9, A857-A857.		1
149	A phase II study of biomarker-driven early discontinuation of antiâ€“PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.. Journal of Clinical Oncology, 2022, 40, TPS9591-TPS9591.	0.8	1
150	Reply to A. Indini et al. Journal of Clinical Oncology, 2016, 34, 1018-1019.	0.8	0
151	Evaluating Chemotherapy at the End of Life. JAMA Oncology, 2016, 2, 142.	3.4	0
152	Mucosal melanoma: epidemiology, biology, management and the role of immunotherapy. Expert Opinion on Orphan Drugs, 2017, 5, 945-952.	0.5	0
153	A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.. Journal of Clinical Oncology, 2015, 33, TPS9089-TPS9089.	0.8	0
154	Frequency of actionable somatic alterations with genomic profiling: the Columbia University experience.. Journal of Clinical Oncology, 2016, 34, e23132-e23132.	0.8	0
155	Outcomes of melanoma brain metastases treated with stereotactic radiosurgery with and without concurrent immune checkpoint therapy.. Journal of Clinical Oncology, 2017, 35, e21026-e21026.	0.8	0
156	Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.. Journal of Clinical Oncology, 2017, 35, TPS9597-TPS9597.	0.8	0
157	Clonal evolution of uveal melanoma metastases.. Journal of Clinical Oncology, 2018, 36, e21534-e21534.	0.8	0
158	Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).. Journal of Clinical Oncology, 2022, 40, TPS9610-TPS9610.	0.8	0
159	ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9609-TPS9609.	0.8	0